Data Year:

For its 2025 fiscal year, Jasper Therapeutics, Inc., listed the following executives on its annual proxy statement to the SEC

Equity
Cash Compensation
Other
Fiscal Year Ended in 2025
Name And Title Total Compensation Pay Rank By Title In Biotechnology industry
Jeet Mahal
Chief Executive Officer and President; Former Chief Operating Officer
Total Compensation $1,289,599 View details Pay Rank By Title In Biotechnology industry #126 View more
Ronald Martell
Former Chief Executive Officer and President
Total Compensation $2,494,099 View details Pay Rank By Title In Biotechnology industry #418 View more
Herb Cross
Chief Financial Officer and Corporate Secretary
Total Compensation $1,283,474 View details Pay Rank By Title In Biotechnology industry #331 View more
Edwin Tucker
Former Chief Medical Officer
Total Compensation $1,537,032 View details Pay Rank By Title In Biotechnology industry #206 View more

The charts on this page feature a breakdown of the total annual pay for the top executives at Jasper Therapeutics, Inc. as reported in their proxy statements.

Total Cash Compensation information is comprised of yearly Base Pay and Bonuses. Jasper Therapeutics, Inc. income statements for executive base pay and bonus are filed yearly with the SEC in the edgar filing system. Jasper Therapeutics, Inc. annual reports of executive compensation and pay are most commonly found in the Def 14a documents.

Total Equity aggregates grant date fair value of stock and option awards and long term incentives granted during the fiscal year.

Other Compensation covers all compensation-like awards that don't fit in any of these other standard categories. Numbers reported do not include change in pension value and non-qualified deferred compensation earnings.

Name And Title Total Cash Equity Other Total Compensation
Jeet Mahal
Chief Executive Officer and President; Former Chief Operating Officer
Total Cash $610,050 Equity $679,549 Other $0 $1,289,599
Ronald Martell
Former Chief Executive Officer and President
Total Cash $727,272 Equity $1,766,827 Other $0 $2,494,099
Herb Cross
Chief Financial Officer and Corporate Secretary
Total Cash $603,925 Equity $679,549 Other $0 $1,283,474
Edwin Tucker
Former Chief Medical Officer
Total Cash $312,673 Equity $679,549 Other $544,810 $1,537,032
For its 2024 fiscal year, Jasper Therapeutics, Inc., listed the following board members on its annual proxy statement to the SEC.
Name Total COMPENSATION
Anna French, D.Phil. Total Cash $29,330
Christian Nolet Total Cash $226,489
Judith Shizuru, M.D., Ph.D. Total Cash $457,789
Kurt von Emster Total Cash $228,289
Scott Brun, M.D. Total Cash $217,789
Svetlana Lucas, Ph.D. Total Cash $324,034
Tom Wiggans Total Cash $231,489
Vishal Kapoor Total Cash $212,989
Browse Board of Directors By First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Executives by First Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Browse Companies by Company Name
A B C D E F G H I J K L M N O P Q R S T U V W X Y Z

This report is not for commercial use. Thorough reviews have been conducted to assure this data accurately reflects disclosures. However for a complete and definitive understanding of the pay practices of any company, users should refer directly to the actual, complete proxy statement.

Use of Data / Disclaimer

The information shown here is a reporting of information included in the company's proxy statement. The proxy statement includes footnotes and explanations of this information plus other information that is pertinent in assessing the overall value and appropriateness of the compensation information. For those interested in conducting a detailed compensation analysis, we recommend that you review the entire proxy statement. You may retrieve the full proxy statement by going to the Securities and Exchange Commission (SEC) website at www.sec.gov and entering the company's name and then looking in the first column for an entry of "Form DEF 14A" (or any similar code). You may also find the annual proxy statement by going directly to the company's website.

What is a proxy statement?

A proxy statement (or "proxy") is a form that every publicly traded U.S. company is required to file with the U.S. Securities & Exchange Commission (SEC) within 120 days after the end of its fiscal year. The proxy must be sent to every shareholder in advance of the company's annual shareholders meeting. All proxy statements are public filings made available to the general public by the SEC.

The proxy statement's main purpose is to alert shareholders to the annual meeting and provide them information about the issues that will be voted on during the annual meeting, including decisions such as electing directors, ratifying the selection of auditors, and other shareholder-related decisions, including shareholder-initiated initiatives. Also, proxies must disclose specific detailed information regarding the pay practices for certain executives.